Tomoko Kataoka

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Kohei Nakachi, Masafumi Ikeda, Masaru Konishi et al. · The Lancet · 2023 · 214 citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +9

Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial

Keiju Aokage, Kenji Suzuki, Hisashi Saji et al. · The Lancet Respiratory Medicine · 2023 · 194 citations

Surgical Oncology, Phase 3, Medicine +10

Induction of apoptosis by gallic acid in human stomach cancer KATO III and colon adenocarcinoma COLO 205 cell lines.

Kazumi Yoshioka, Tomoko Kataoka, Toshiya Hayashi et al. · Oncology Reports · 2000 · 104 citations

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma et al. · JAMA Oncology · 2022 · 85 citations · Full text

A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

Masato Ozaka, Kohei Nakachi, Satoshi Kobayashi et al. · European Journal of Cancer · 2022 · 74 citations · Full text